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Quality control of multiplex 
antibody detection in samples from 
large-scale surveys: the example of 
malaria in Haiti
Lotus L. van den Hoogen1*, Jacquelin présumé2, ithamare Romilus2, Gina Mondélus2, 
tamara elismé2, nuno Sepúlveda1,3, Gillian Stresman1, thomas Druetz4,5, Ruth A. Ashton4, 
Vena Joseph4, thomas p. eisele4, Karen e. S. Hamre6,7, Michelle A. chang6, Jean f. Lemoine8, 
Kevin K. A. tetteh1, Jacques Boncy2, Alexandre existe2, chris Drakeley1 & eric Rogier6
Measuring antimalarial antibodies can estimate transmission in a population. to compare outputs, 
standardized laboratory testing is required. Here we describe the in-country establishment and quality 
control (QC) of a multiplex bead assay (MBA) for three sero-surveys in Haiti. Total IgG data against 21 
antigens were collected for 32,758 participants. Titration curves of hyperimmune sera were included 
on assay plates, assay signals underwent 5-parameter regression, and inspection of the median and 
interquartile range (IQR) for the y-inflection point was used to determine assay precision. The medians 
and IQRs were similar for Surveys 1 and 2 for most antigens, while the IQRs increased for some antigens 
in Survey 3. Levey-Jennings charts for selected antigens provided a pass/fail criterion for each assay 
plate and, of 387 assay plates, 13 (3.4%) were repeated. Individual samples failed if IgG binding to the 
generic glutathione-S-transferase protein was observed, with 659 (2.0%) samples failing. An additional 
455 (1.4%) observations failed due to low bead numbers (<20/analyte). The final dataset included 
609,438 anti-malaria IgG data points from 32,099 participants; 96.6% of all potential data points if no 
Qc failures had occurred. the MBA can be deployed with high-throughput data collection and low inter-
plate variability while ensuring data quality.
Measurement of antibody responses to malaria at the population-level can describe recent and historical trans-
mission patterns1–4 and is informative for malaria research and program policies5–7. Antibodies can be quan-
titatively measured by a variety of techniques including the enzyme-linked immunosorbent assay (ELISA) 
and multiplex bead assays (MBAs). The latter allows the simultaneous detection of antibodies to multiple 
antigenic targets and has been utilized now for Plasmodium serology for over a decade8. Since the advent of 
Plasmodium-specific MBAs, numerous assay optimisation and implementation studies9–17, as well as epidemio-
logical application studies18–21, have been published by various groups.
In generating responses to many antigens simultaneously, MBAs have the advantage of reducing needed 
reagent quantities, sample volume, and time in the laboratory compared to the ELISA8,9. Assays of any type 
require controls or standards to assess variability across runs or batches and to compare research studies, and 
with a broad panel of antigens in the MBA, it is potentially difficult to find standards for all targets being assayed. 
Recently, standardization using curves of known concentrations of total human IgG has been suggested, but this 
was problematic in showing insufficient reproducibility between operators13. Moreover, these do not allow for 
the assessment of antigen-specific responses which are important for quality control in assessing the stability of 
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specific antibodies over time. In-house pools of hyperimmune sera are commonly employed for serological stud-
ies, and recently, a World Health Organization (WHO) reference Plasmodium falciparum (Pf) serological stand-
ard has been developed by the National Institute for Biological Standards and Control (NIBSC)22. This standard 
has previously been tested in a MBA panel of 40 malarial and non-malarial antigens15.
Previous studies on the application and validation of the MBA have shown its correlation with ELISA8,10,12,17,23, 
stability and reproducibility of coupled beads10,12,16,24, use of detection antibodies for Ig classes15 and IgG sub-
classes11,15, as well as consistency between mono- versus multiplex results10,12,15–17. Although intra- and inter-assay 
variability for antimalarial antibodies have been discussed before10,13,14,16,25, and analytical methodologies have 
been evaluated to determine inter-assay variability24,26,27, few have formally assessed variability in large-scale pop-
ulation surveys (i.e., studies involving thousands to tens of thousands of samples over time)16. Here, we discuss 
the in-country establishment and quality control process for multiplex antimalarial antibody (IgG) detection for 
multiple large-scale malaria surveys performed in Haiti in 2017.
Results
Assay throughput. Dried blood spots (DBS) were collected in three cross-sectional surveys in central and 
southwestern Haiti in 201728. IgG antibody responses were successfully collected across 21 antigens (Table 1; 17 P. 
falciparum antigens, 2 non-P. falciparum Plasmodium antigens and 2 non-malarial antigens) using a multiplex 
bead assay (MBA; see methods and29). From all collected survey samples that were processed at the Haitian 
national laboratory, minor loss of field samples was found due to data management issues (e.g., incorrect barcodes 
due to accidental typing while scanning barcodes in the laboratory or no blood sample recorded/collected in the 
field) or loss of DBS between field collection and laboratory assessment (Table 2). Thus, the majority of samples 
provided data appropriate for analyses: 99.2% (5,956/6,006) for Survey 1; 99.6% (21,801/21,891) for Survey 2; 
and 99.3% (5,001/5,034) for Survey 3. Laboratory work involved 71 assay plates over five weeks for Survey 1; 257 
plates over nine weeks for Survey 2; and 59 plates over four weeks for Survey 3. Together these represent 32,758 
participant samples processed over an eighteen-week period. After removal of median fluorescence intensity 
(MFI) data across all analytes for samples with missing or high responses to the generic glutathione-S-transferase 
(GST, n = 659, 2.0%; Supplementary Fig. 1), 5,898 samples passed QC in Survey 1 (99.0% of those received at 
the laboratory); 21,234 samples in Survey 2 (97.4%); and 4,967 samples in Survey 3 (99.3%). Removal of single 
analytes’ datapoints due to low bead counts accounted for additional minor loss of data (n = 455 observations, 
0.07% of all observations). Following these QC checks, there were 673,624 unique IgG observations across the 21 
included antigens (Table 2).
Robust responses for both positive control standards. A Haitian positive serum control pool (HP) 
was created using country-wide DBS samples from individuals with confirmed malaria (n = 63) previously col-
lected during healthcare visits. A 6-point, 5-fold titration curve of the HP standard starting at 1:200 was included 
on every plate, while one using the WHO Pf 10/198 NIBSC standard22 was included on one plate per day (starting 
at 1:100). The highest concentrations of both the HP and the NIBSC positive control standard curves showed 
robust IgG responses for nearly all of the included Pf antigens (Fig. 1). Generally higher MFI responses were seen 
in the NIBSC standard, likely due in part to the higher serum concentration. The lowest MFI responses were 
recorded to the HRP2 and Hyp2 antigens in both standards (median MFI < 500 before log-transformation).
inter-plate variability. Levey-Jennings plots of IgG responses of the third point of the HP standard curve are 
shown in Fig. 2. Values on assay plates that fell outside of the 2 standard deviation (SD) range of mean responses 
for two out of three highly immunogenic antigens (GLURP-R2, PfAMA-1 and PfMSP-119) were selected to be 
repeated: 2 plates in Survey 1, 9 plates in Survey 2, and 2 plates in Survey 3 (13/387 total assay plates, 3.4%). 
Upon repetition, all 13 of these assay plates passed the QC check and provided useable serological data. When 
comparing 2 to 5 parameter logistic regression fits for standard curves values, the 5-parameter logistic regression 
fit showed the smallest sum of squared errors for the HP curve for the majority of antigens and plates (≥88%; 
Supplementary Table 1) and thus was used for all standard curves for further analysis. HP standard curves per 
survey are shown in Fig. 3 for all antigens except HRP2 and Hyp2 (which were unable to be fitted to curves), 
and curves for the NIBSC standard are shown in Supplementary Fig. 2. Inspection of the median and IQR of 
the y-inflection point was used to assess within and between survey variation in standard curves (Fig. 4). The 
median and length of the IQR of y-inflection points was similar for Survey 1 and Survey 2 for most antigens; 
except for a smaller recorded Survey 2 median for MSP2_CH150/9 (i.e., below the 25th percentile of Survey 1) 
as well as a larger Survey 2 IQR for PfMSP-119, MSP2_CH150/9, SBP1 and to a lesser extent MSP2_Dd2. The 
length of the IQR for y-inflection points was generally highest in Survey 3. While for most antigens the median 
Survey 3 y-inflection point was similar to Survey 1 and 2, a smaller Survey 3 median (i.e., below the 25th per-
centile of Survey 2) was recorded for MSP2_CH150/9, MSP2_Dd2, GEXP18 and borderline for SBP1. Standard 
curves for Pf, P. vivax (Pv) and P. malariae (Pm) MSP-119 antigens with the HP and NIBSC standard are shown in 
Supplementary Fig. 3.
Discussion
In this study set in Haiti, we described the in-country establishment and quality control of an MBA simultane-
ously detecting IgG responses to 17 P. falciparum recombinant antigens and peptides and 4 additional non-P. 
falciparum antigens. Laboratory antibody measurements were collected for 32,758 participant samples across 
three surveys in eighteen weeks. Results for only 0.2–0.5% of the participants for each of the three surveys had 
to be removed due to high GST responses (i.e., evidence for non-specific IgG binding). The data collected for the 
remaining participants represent 545,683 P. falciparum serological data points of which only 414 (0.08%) had 
to be removed due to well-specific errors such as low bead counts. The quality control to assess the inter-plate 
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precision of the assay was based on a specifically created positive control standard of RDT positive Haitians with 
high titers of anti-Pf antibodies (Haitian hyperimmune sera pool: HP). The rationale for creation of the HP stand-
ard was that it would most accurately represent seroresponses of the Haitian populace to the locally circulating 
P. falciparum parasites. In addition, we included the WHO Pf 10/198 NIBSC reference standard on one plate per 
day to compare for consistency among days22. The MBA was implemented in this setting as a high-throughput 
tool enabling rapid turnaround of antibody measurements for malaria epidemiological surveys.
Inter-plate variability was assessed using Levey-Jennings plots which showed no trends in loss or gain of IgG 
responses in the HP standard over time. Minor plate-to-plate variation in MFI values was observed during assay 
processing, and could have been caused by inter-technician variability, pipetting errors or fluctuations in labo-
ratory temperatures and/or incubation time during assay processing. For this specific study, plate values that fell 
outside the mean +/−2 SD of responses in the third point of the HP standard curve (i.e., the third point in the 
six-point dilution series of the HP standard) for two out of three highly immunogenic targets were repeated as 
Antigen Alias Pathogen Description Location
Purification 
Tag Strain Rationale
Coupling 
Conc. (µg/
mL beads)
Coupling 
pH Reference
Etramp 4 Ag 2 etr42 P. falciparum Early transcribed membrane antigen iRBC, PVM GST 3D7 Recent Pf exposure* 115 7.2
4; K.K.A. Tetteh 
unpublished
Etramp 5 Ag 1 etr51 P. falciparum Early transcribed membrane antigen iRBC, PVM GST 3D7 Recent Pf exposure* 100 7.2
35; K.K.A. Tetteh 
unpublished
GEXP18 gexp P. falciparum Gametocyte exported protein 18
iRBC/
Gametocyte GST 3D7 Recent Pf exposure* 200 7.2
4; K.K.A. Tetteh 
unpublished
H103 h103 P. falciparum H103/merozoite surface protein 11
Merozoite 
surface/
rophtry neck
GST 3D7 Pf exposure 100 7.2 36
HRP2 hrp2 P. falciparum Histidine rich protein 2
iRBC and 
secreted GST Type A and B Pf exposure 25 5.0
37
HSP40 Ag1 hsp40 P. falciparum Heat shock protein 40 iRBC GST 3D8 Recent Pf exposure* 100 7.2
4; K.K.A. Tetteh 
unpublished
Hyp 2 hyp2 P. falciparum Plasmodium exported protein
Hypothesised 
location: iRBC GST 3D7 Recent Pf exposure* 1000 7.2
4; K.K.A. Tetteh 
unpublished
LSA-1 lsa1 P. falciparum Liver surface antigen 1
Infected 
hepatocyte N/A
Synthesized 
peptide, 
Pl1043 
epitope
Pf exposure  
(liver stage) 60 5.0
38
MSP2 
CH150/9 msp2_ch150 P. falciparum
CH150/9 allele of 
MSP2; full-length
Merozoite 
surface GST CH150/9 Pf exposure 5 5.0
39
MSP2 Dd2 msp2_dd2 P. falciparum Dd2 allele of MSP2; full-length
Merozoite 
surface GST Dd2 Pf exposure 20 5.0
40
PfAMA1 ama1 P. falciparum Apical membrane antigen 1 Micronemes His FVO Pf exposure 15 7.2
41
PfGLURP R0 glurp0 P. falciparum Glutamate rich protein R0
Merozoite 
surface N/A
Synthesized 
peptide, R0 
fragment
Pf exposure 30 5 18
PfGLURP R2 glurp2 P. falciparum Glutamate rich protein R2
Merozoite 
surface Hisx6 F32 Pf exposure 15 7.2
42
PfMSP-119 msp119 P. falciparum
19 kDa fragment of 
MSP1 molecule
Merozoite 
surface GST Wellcome Pf exposure 20 7.2
43
PfSEA1 sea P. falciparum Schizont egress antigen iRBC GST 3D7 Pf exposure 20 5
44; K.K.A. Tetteh 
unpublished
PmMSP-119 pmmsp119 P. malariae
19 kDa fragment of 
MSP1 molecule
Merozoite 
surface GST Pm China I Pm exposure 20 5
45
PvMSP-119 pvmsp119 P. vivax
19 kDa fragment of 
MSP1 molecule
Merozoite 
surface GST Pv Belem Pv exposure 20 5
45
rCSP rcsp P. falciparum Circumsporozoite surface protein Sporozoite N/A 3D7
Recent Pf exposure* 
(sporozoite stage) 60 7.2
46
SBP1 sbp1 P. falciparum
Skeleton-binding 
protein; Maurer’s 
cleft.
iRBC GST 3D7 Pf exposure 15 5
47; K.K.A. Tetteh 
unpublished
GST gst S. japonicum Glutathione S-transferase
Correct for 
background 
reactivity due to 
GST-tag
20 5 J. Priest/CDC
Tetanus 
Toxoid tt C. tetani Tetanus Toxoid
Vaccination target: 
internal “positive” 
control
12.5 5
Massachusetts 
Biologic 
Laboratories
Table 1. Characteristics of multiplex bead assay antigen panel for three malaria transmission surveys in Haiti. 
*Associated with recent Pf exposure as described in ref. 4. Conc.: concentration. iRBC: infected red blood cell. 
PVM: parasitophorous vacuole membrane. kDa: k ilodalton. Pf: Plasmodium falciparum. Pv: Plasmodium vivax. 
Pm: Plasmodium malariae. N/A: not applicable.
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previously described by others16. Using multiple targets for this selection compared to one target avoids rejecting 
a plate due to well-specific errors such as low bead counts or pipetting errors. This multi-antigen methodology 
also allows for pragmatic selection of truly problematic assay plates, since comprehensive errors (i.e., adding 
wrong amounts of detection reagents, improper incubation time) would affect all antigens’ MFI readings on the 
entire plate and decreased or elevated signals would be seen throughout the whole antigen panel.
Survey 1 Survey 2 Survey 3
Plates, n 71 257 59
Samples, n
Proportion of previous n
  Collected in the field 6006 21891 5034
  Received/processed at the lab 595699.17%
21801
99.59%
5001
99.34%
  GST reading available 592299.43%
21336
97.87%
4989
99.76%
  Acceptable GST reactivity 589899.59%
21234
99.52%
4967
99.56%
Observations*, n
Loss, n
  All antigens (n = 21)
Loss
123,850
8
445,787
127
103,987
320
  Plasmodium antigens (n = 19)
Loss
112,054
8
403,325
121
94,059
314
  P. falciparum antigens (n = 17)
Loss
100,260
6
360,872
106
84,137
302
Table 2. Number of samples and observations for which Immunoglobulin G (IgG) antibody responses were 
successfully collected using a multiplex bead assay across three malaria transmission surveys in Haiti. *Unique 
IgG observations successfully collected (i.e. number of participants multiplied by number of antigens/peptides 
to which antibody responses were collected). GST: glutathione-S-transferase.
Figure 1. Antibody reactivity profile of hyperimmune sera standards used in this study. MFI: Median 
fluorescence intensity; values were corrected for background reactivity of blank responses and natural 
log transformed (y-axis). HP: Haitian hyperimmune sera pool (for details see main text). NIBSC: WHO 
Plasmodium falciparum 10/198 NIBSC standard. The HP curve was run on every plate, while the NIBSC curve 
was run on one plate per day. Responses to the first point of the curve are shown, with a serum concentration 
of 1:200 for the HP and 1:100 for the 10/198 standard. For antigen (x-axis) abbreviations see Table 1, antigens 
are ordered by descending median HP responses. In addition to malarial antigens, tetanus toxoid (tt) and 
glutathione S-transferase (gst) responses are shown (right side of dashed vertical black line).
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Inter-plate variability was further assessed using 5-parameter logistic regression for standard curves on each 
plate26,30. Inspection of the median and IQR of the y-inflection point was used to assess within and between sur-
vey variation in standard curves. The median y-inflection points were similar for Survey 1 and Survey 2 for most 
antigens with narrow IQRs, and the length of the IQR for y-inflection points was generally highest in Survey 3. 
For four of the included targets, the standard curves revealed a loss of reactivity over time (MSP2_Dd2, MSP2_
CH150/9, GEXP18 and SBP1). As beads were coupled in one batch at the start of Survey 1 to exclude variations 
between bead batches, the loss in reactivity may be explained by these antigens covalently bound to the microbe-
ads as being less stable after long-term storage, or degradation or loss of binding capacity of the IgG antibodies in 
the HP standard. Therefore, comparison of results among the three surveys for these targets should be interpreted 
with caution and future use of these antigens would need to optimise storage and binding conditions.
The application of the WHO Pf 10/198 NIBSC standard to the MBA was recently described by Ubillos et al. 
where they showed robust IgG responses to 23 antigens, 20 of which were previously described malarial antigenic 
targets15. Here, we reported IgG antibody responses in this reference standard to 14 novel recombinant malarial 
antigens of which 12 showed robust responses (IgG against Hyp2 and HRP2 did not). Antibody responses to Pf-, 
Pv- and Pm-MSP-119 antigens were similar to those described when the reference standard was developed and 
tested on ELISA by showing high titers for the Pf- and Pm-MSP-119 targets, and negligible IgG against PvMSP-
11922. By adding this WHO Pf 10/198 NIBSC standard to one plate per day alongside the newly developed hyper-
immune pool of Haitian sera on every plate, we were able to confirm the presence or absence of trends over time 
in antigen-specific results. However, standard curves from this NIBSC standard pool were more variable between 
plates and surveys. This could partly be explained by the smaller sample size (i.e., less curves were run for the 
entire study), stability of the sera over time, or potentially this standard may be more sensitive to day-to-day var-
iations in incubation times during assay processing.
Others have shown that combining antibody responses to multiple targets more accurately reflects recent 
malaria infection than to one antigen though at small increments4,31,32. The fact that this study showed that mul-
tiplex antimalarial antibody data could be collected accurately at scale aids in ensuring representation of the var-
iation in human immune responses. Additional longitudinal studies collecting multiplex antimalarial antibody 
data following natural infections across varied settings are needed to identify which antigens best reflect exposure 
histories.
In this study, we have described the successful in-country establishment of the MBA with highly efficient 
throughput and acceptable inter-plate variability for well-characterised malaria antigenic targets in Haiti. This 
assay allows for rapid assessment of the exposure history of populations which can directly inform malaria 
Figure 2. Levey-Jennings charts of antibody responses in the standard of Haitian hyperimmune sera pool 
across all plates per survey. MFI: Median fluorescence intensity; values were corrected for background reactivity 
of blank responses and natural log transformed. HP: Haitian hyperimmune sera pool (for details see main text). 
Responses in the third dilution point of the curve (serum concentration of 1:5,000) per plate are shown across 
three surveys. The mean plus/minus two times the standard deviation of responses in the third dilution point of 
the curve per survey and antigen are shown in dashed red lines.
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stratification and targeting of interventions. However, inter-plate variability was considerable for some of the 
newly described targets with lower immunogenicity. IgG antibodies to these targets are perhaps more sensitive 
to long-term storage, fluctuations in laboratory temperatures and/or incubation time during assay processing. 
Future work should focus on further optimisation of international assay standards and standardized quality 
assurance/quality control metrics for multiplex antibody detection assays.
Methods
Study population. Three cross-sectional surveys were conducted in 2017 in Haiti: two in the Artibonite 
valley of central Haiti (Survey 1 in May-Jun and Survey 2 in Jul-Oct with a two-week pause due to hurricanes), 
and one in Grand’Anse department in south-western Haiti (Survey 3 in Nov-Dec). In 2017, malaria incidence in 
the Grand’Anse department was estimated at 18.1 per 1,000 inhabitants while this was 0.6 per 1,000 in Artibonite 
(source: National Malaria Control Program, PNCM, Haiti). Survey design and enrollment procedures have been 
described elsewhere28. The number of participants providing a blood sample in each survey included, Survey 1: 
6,006 participants, Survey 2: 21,891 and Survey 3: 5,034. In the former two surveys, finger-prick capillary blood 
was collected in microtubes (Safe-T-Fill Capillary Blood Collection Systems: EDTA, RAM Scientific Inc.) and 
pipetted on Whatman 903 cards (GE Healthcare) within 24 hours, whereas in the latter survey, blood was spotted 
directly onto the Whatman 903 cards at point-of-contact. In all surveys, cards were dried overnight and packed 
the next day in individual bags with silica gel. These dried blood spots (DBS) were kept at room temperature and 
were transported to the national laboratory (Laboratoire National de Santé Publique, LNSP) in Port-au-Prince 
once per week where they were stored at 4 °C until processed. Participants were also tested with a rapid diagnostic 
test (RDT, SD Bioline Malaria Antigen Pf.; 05FK50) and treated according to national guidelines if positive28.
Figure 3. Average standard curves of the standard of Haitian hyperimmune sera pool for each survey. MFI: 
Median fluorescence intensity; values were corrected for background reactivity of blank responses and natural 
log transformed. HP: Haitian hyperimmune sera pool (for details see main text). MFI values were converted 
to proportions using the minimum and maximum MFI value for all standard curves across all antigens (2.07 
and 11.17 respectively). For each plate and antigen, standard curves were fitted using 5-parameter logistic 
regression. Standard curves were only fitted if the non-log-transformed MFI of at least one of the dilution 
points was larger than 100. Using the curve parameters, MFI values were predicted across a sequence of 200 
values of standard curve concentrations for each of the plates. Standard curves per survey were plotted using the 
generalized additive model method and the interquartile range is shown in vertical lines at each of the dilution 
steps of the standard curve. For antigen abbreviations see Table 1, malaria antigens are ordered from top left to 
bottom right by median responses as shown in Fig. 1. In addition to malarial antigens, results for tetanus toxoid 
(tt) are shown.
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Antigen coupling to beads. Antigens were covalently coupled to unique bead regions as previously 
described by Rogier et al.19,29. In addition to the malarial antigen panel, the glutathione-S-transferase (GST) pro-
tein was included as a generic antigen to correct for potential non-specific binding. In addition, this served as an 
internal control as many of the recombinant malaria antigens were GST fused. Tetanus toxoid (TT, Massachusetts 
Biologic Laboratories) was included to act as an internal positive control as vaccinated Haitians would show 
responses to this target. Antigen characteristics and details on antigen to bead coupling conditions are depicted 
in Table 1.
Assay standards. A Haitian positive serum control pool (HP) was created using country-wide DBS sam-
ples from RDT positive individuals collected during healthcare visits. Blood spots from 63 participants with 
high responses to a range of Pf antigens were combined and eluted in Buffer B (phosphate-buffered saline (PBS) 
containing 0.5% BSA, 0.05% Tween 20, 0.02% sodium azide, 0.5% polyvinyl alcohol, 0.1% casein, 0.8% poly-
vinylpyrrolidone and 0.5% w/v E. coli extract) to a whole blood dilution of 1:50 which corresponds to serum 
dilution of approximately 1:100. The approximate serum concentration is used to indicate the dilution factor 
throughout the remainder of this report. A 6-point titration curve of the Haitian hyperimmune sera was created 
in bulk, stored at 4 °C and used on each assay plate. The first point of this HP curve was a dilution of 1:100 and 
titrated by 5-fold, meaning the second point was 1:500 up to the sixth point at 312,500. The WHO Pf 10/198 
NIBSC standard22 was eluted in 1.0 ml of dH20 (1:5 serum concentration, 100 units) and diluted further in 
Buffer B. As with the HP curve, a 6-point curve (starting at 1:50) of 5-fold dilutions was prepared in bulk for use 
throughout the whole study and stored at 4 °C. As samples and controls were diluted 1:2 into assay plates (see 
below), final starting concentrations for the first points of the titration curves were 1:200 (HP) and 1:100 (NIBSC) 
and remaining dilution points in titration curves followed accordingly. Unlike the HP curve, the NIBSC standard 
curve was only run on a single assay plate every day. In addition, two blanks (buffer B only) were run on each 
plate.
Multiplex bead assay. Sample preparation and the MBA for data collection have been described else-
where29. Briefly, blood elution for each sample was completed by taking one 3 mm spot from the centre of a DBS 
and eluting overnight in 173 µl of buffer B to create a 1:100 serum dilution for each sample. Samples were sealed 
in holding plates for storage at 4 °C and tested within three weeks of blood elution. For the assay, a mixture of all 
bead regions was prepared by adding 6 µl per coupled bead region (62,500 beads/antigen/plate) in 5 ml of Buffer 
A (PBS containing 0.5% BSA, 0.05% Tween-20, 0.02% sodium azide) for each plate. The bead mixture was mixed 
using a serological pipette and 50 µl was added to each well of a 96-well BioPlex Pro plate (Bio-Rad). Plates were 
placed on handheld magnetic separators (Luminex Corporation) and washed two times with wash buffer (PBS 
containing 0.05% Tween-20). After removing plates from the separator, 50 µl of reagent mixture in Buffer A (1:500 
Figure 4. Median and interquartile range of predicted y-inflection points of standard curves per survey using 
the standard of the Haitian hyperimmune sera pool. Median (shapes) and interquartile range (vertical lines) of 
the predicted y-inflection points from standard curves across all plates using 5-parameter logistic regression are 
shown per survey. For antigen (x-axis) acronyms see Table 1, malaria antigens are ordered by median responses 
as shown in Fig. 1. In addition to malarial antigens, results for tetanus toxoid (tt) are shown (right side of dashed 
vertical black line).
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biotinylated anti-human IgG, Southern Biotech; 1:625 biotinylated anti-human IgG4, Southern Biotech; and 1:200 
Streptavidin conjugated to phycoerythrin, Invitrogen) was added to each well followed by 50 µl of eluted blood 
sample. Plates were incubated on a shaker overnight at room temperature at 600 rpm protected from light. The 
next day, plates were washed three times and 100 µl PBS was added to resuspend beads. Plates were shaken lightly 
for 30 minutes and read with the MAGPIX machine (Millipore) using Bio-Plex Manager MP (Bio-Rad) software 
with a target of 50 beads/antigen/well. Median fluorescence intensity (MFI) was recorded for each sample and 
corrected for background reactivity by subtracting blank values on each plate (Buffer B only) by antigen (MFI 
corrected for background, hereafter: MFI). Results were exported to Excel workbooks by plate.
Statistical analyses. All statistical analyses were performed in R Studio version 3.3.333. Participant samples 
with GST MFI levels above a threshold of 1,000 were excluded from further analyses as evidence of non-specific 
binding. All MFI values were log transformed with MFI values smaller than background responses replaced with 
the median background values for all antigens (background non-log transformed MFI of 7.90; interquartile range: 
6.70–8.90). The value of the third point of the HP standard curve of each plate was plotted in Levey-Jennings 
charts. Plates that fell outside of the mean +/−2 standard deviations (SD) for two out of three highly immu-
nogenic antigens (GLURP-R2, AMA-1 and MSP-119) were repeated16. Logistic regression curves were fitted to 
standard curve values per plate using the nplr package in R Studio34, which compares 2 to 5 parameter logistic 
regression fits and selects the fit with the smallest sum of squared errors. Logistic regression was only fit if no 
more than one value of the standard curve was missing and at least one of the recorded MFI values was >4.61 
(i.e., MFI 100 before log-transformation). MFI values were first converted to proportions using the minimum and 
maximum MFI values for all standard curves across all antigens (2.07 and 11.17, respectively). The 5-parameter 
logistic regression is given below:
= +
−
+ −⁎
y B T B
[1 10 ]b xmid x
s( ( ))
where B and T are the bottom and top asymptotes, b and xmid are the Hill slope and the x-coordinate at the 
inflection point and s is an asymmetry coefficient. In 4-parameter logistic regression, the s parameter is forced to 
be 1, while 3- or 2-parameter logistic regression force B and T to be 0 and 1, respectively. Curve parameters were 
recorded for each plate as well as a sequence of 200 predicted MFI values across standard curve concentrations to 
represent the fitted curves.
ethics approval and consent to participate. Survey 1 and Survey 3 were approved by the LSHTM 
Research Ethics Committee (10393), Tulane Institutional Review Board (794709) and the National Bioethics 
Committee in Haiti (1516-30). The Center for Global Health Associate Director of Science reviewed and approved 
the protocol for ethical compliance for CDC’s level of engagement. Survey 2 was approved by CDC Institutional 
Review Board (6821), LSHTM Research Ethics Committee (10466) and the National Bioethics Committee in 
Haiti (1516-29 and 1617-31). All participants provided informed written consent or assent and blood collec-
tion adhered to the approved protocols. All research was performed in accordance with relevant guidelines and 
regulations.
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